

NEWSLETTER

Volume 5, December 2022



UPDATE

- 25 Institutional partners
- 481 professionals registered as members
- Successful 2nd Annual meeting in association with SOHO
 - 502 Participants
 - 85 Abstracts
- The annual meeting session recordings are available on HCC website
<https://www.hemecancer.org/>



64TH ASH ANNUAL MEETING 2022 6 ABSTRACTS ACCEPTED

- Low Dose Dasatinib Is Not As Active in a CML CP Cohort Enriched with Intermediate/High-Risk CML Chronic Phase: A Phase IIb Multi-Center Trial
- Real world data on unique challenges and outcomes of older patients with AML from resource limited settings: Hematology Cancer Consortium INWARD registry
- Acute Myeloid Leukemia during the COVID Pandemic: Impact and the Indian Experience
- Prognostic Factors and Outcomes of Adolescent and Adult Burkitt Lymphoma and Leukemia from a Low-Middle Income Country: An Experience from Hematology Cancer Consortium
- Induction Related Mortality Score in Acute Myeloid Leukemia: Prospective Validation Study (pRISM) of the Hematology Cancer Consortium (HCC)
- Real-World Outcomes for Acute Promyelocytic Leukemia: Need to Address Induction Mortality

WE ACKNOWLEDGE THE FOLLOWING INDUSTRY PARTNERS FOR SUPPORTING THE 2ND ANNUAL MEETING

- BDR Pharmaceuticals International Pvt Ltd
- Bristol Myers Squibb India Pvt Ltd
- Cipla Ltd
- Dr. Reddy's Laboratories Ltd
- Emcure Pharmaceutical Ltd
- Glenmark Pharmaceuticals Ltd
- Intas Pharmaceuticals Ltd
- Janssen India oncology
- MSD Pharmaceuticals Pvt Ltd
- Natco Pharma Ltd
- Novartis Healthcare
- Pfizer Products India Pvt Ltd
- Roche Pharmaceutical Ltd
- Sanofi Healthcare Pvt Ltd
- Zydus Lifesciences Ltd

**WISHING ALL OUR PARTNERS, MEMBERS, AND SUPPORTERS A
HAPPY AND PROSPEROUS NEW YEAR**